The impact of FK506 on graft coronary disease of rat cardiac allograft - A comparison with cyclosporine

Sadahiko Arai, S. Teramoto, Y. Senoo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We studied the impact of FK506, a potent immunosuppressant, on graft coronary disease and graft-infiltrating lymphocyte subset after rat heart transplantation. Fisher rat heart grafts transplanted into Lewis rat recipients were divided into three groups: control (n = 7), rats treated with FK506 at a dose of 0.32 mg/kg/day intramuscularly (n = 7), and rats treated with cyclosporine at a dose of 10 mg/kg/day intramuscularly (n = 7). Grafts were removed on day 71 in the treated groups and on rejection in the control group. We blindly scored graft rejection and graft coronary disease on a scale of 0 to 4. Graft-infiltrating lymphocytes were investigated by flow- cytometric analysis with the following monoclonal antibodies: W3/25, anti- helper T lymphocyte; OX8, antisuppressor and cytotoxic T lymphocyte; and OX39, antiinterleukin-2 receptor. No difference of graft rejection was found between the two treated groups (FK506 1.66 ± 0.49 versus cyclosporine 1.45 ± 0.37), but the FK506 group showed severe graft coronary disease (FK506 2.14 ± 0.82 versus cyclosporine 0.78 ± 0.17; p <0.01) in this model. In flow-cytometric analysis, we found an increased proportion of OX8-positive lymphocytes (FK506 25.7 ± 6.4 versus cyclosporine 4.9 ± 2.4, p <0.01). These results suggest that suppression of cytotoxic T lymphocytes may be involved in graft coronary disease.

Original languageEnglish
Pages (from-to)757-762
Number of pages6
JournalJournal of Heart and Lung Transplantation
Volume11
Issue number4 I
Publication statusPublished - 1992

Fingerprint

Tacrolimus
Cyclosporine
Allografts
Coronary Disease
Transplants
Graft Rejection
Cytotoxic T-Lymphocytes
Lymphocytes
Control Groups
Lymphocyte Subsets
Heart Transplantation
Immunosuppressive Agents
Helper-Inducer T-Lymphocytes
Monoclonal Antibodies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

The impact of FK506 on graft coronary disease of rat cardiac allograft - A comparison with cyclosporine. / Arai, Sadahiko; Teramoto, S.; Senoo, Y.

In: Journal of Heart and Lung Transplantation, Vol. 11, No. 4 I, 1992, p. 757-762.

Research output: Contribution to journalArticle

@article{e5bea7e72c304b4cb1903931f7dd938b,
title = "The impact of FK506 on graft coronary disease of rat cardiac allograft - A comparison with cyclosporine",
abstract = "We studied the impact of FK506, a potent immunosuppressant, on graft coronary disease and graft-infiltrating lymphocyte subset after rat heart transplantation. Fisher rat heart grafts transplanted into Lewis rat recipients were divided into three groups: control (n = 7), rats treated with FK506 at a dose of 0.32 mg/kg/day intramuscularly (n = 7), and rats treated with cyclosporine at a dose of 10 mg/kg/day intramuscularly (n = 7). Grafts were removed on day 71 in the treated groups and on rejection in the control group. We blindly scored graft rejection and graft coronary disease on a scale of 0 to 4. Graft-infiltrating lymphocytes were investigated by flow- cytometric analysis with the following monoclonal antibodies: W3/25, anti- helper T lymphocyte; OX8, antisuppressor and cytotoxic T lymphocyte; and OX39, antiinterleukin-2 receptor. No difference of graft rejection was found between the two treated groups (FK506 1.66 ± 0.49 versus cyclosporine 1.45 ± 0.37), but the FK506 group showed severe graft coronary disease (FK506 2.14 ± 0.82 versus cyclosporine 0.78 ± 0.17; p <0.01) in this model. In flow-cytometric analysis, we found an increased proportion of OX8-positive lymphocytes (FK506 25.7 ± 6.4 versus cyclosporine 4.9 ± 2.4, p <0.01). These results suggest that suppression of cytotoxic T lymphocytes may be involved in graft coronary disease.",
author = "Sadahiko Arai and S. Teramoto and Y. Senoo",
year = "1992",
language = "English",
volume = "11",
pages = "757--762",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "4 I",

}

TY - JOUR

T1 - The impact of FK506 on graft coronary disease of rat cardiac allograft - A comparison with cyclosporine

AU - Arai, Sadahiko

AU - Teramoto, S.

AU - Senoo, Y.

PY - 1992

Y1 - 1992

N2 - We studied the impact of FK506, a potent immunosuppressant, on graft coronary disease and graft-infiltrating lymphocyte subset after rat heart transplantation. Fisher rat heart grafts transplanted into Lewis rat recipients were divided into three groups: control (n = 7), rats treated with FK506 at a dose of 0.32 mg/kg/day intramuscularly (n = 7), and rats treated with cyclosporine at a dose of 10 mg/kg/day intramuscularly (n = 7). Grafts were removed on day 71 in the treated groups and on rejection in the control group. We blindly scored graft rejection and graft coronary disease on a scale of 0 to 4. Graft-infiltrating lymphocytes were investigated by flow- cytometric analysis with the following monoclonal antibodies: W3/25, anti- helper T lymphocyte; OX8, antisuppressor and cytotoxic T lymphocyte; and OX39, antiinterleukin-2 receptor. No difference of graft rejection was found between the two treated groups (FK506 1.66 ± 0.49 versus cyclosporine 1.45 ± 0.37), but the FK506 group showed severe graft coronary disease (FK506 2.14 ± 0.82 versus cyclosporine 0.78 ± 0.17; p <0.01) in this model. In flow-cytometric analysis, we found an increased proportion of OX8-positive lymphocytes (FK506 25.7 ± 6.4 versus cyclosporine 4.9 ± 2.4, p <0.01). These results suggest that suppression of cytotoxic T lymphocytes may be involved in graft coronary disease.

AB - We studied the impact of FK506, a potent immunosuppressant, on graft coronary disease and graft-infiltrating lymphocyte subset after rat heart transplantation. Fisher rat heart grafts transplanted into Lewis rat recipients were divided into three groups: control (n = 7), rats treated with FK506 at a dose of 0.32 mg/kg/day intramuscularly (n = 7), and rats treated with cyclosporine at a dose of 10 mg/kg/day intramuscularly (n = 7). Grafts were removed on day 71 in the treated groups and on rejection in the control group. We blindly scored graft rejection and graft coronary disease on a scale of 0 to 4. Graft-infiltrating lymphocytes were investigated by flow- cytometric analysis with the following monoclonal antibodies: W3/25, anti- helper T lymphocyte; OX8, antisuppressor and cytotoxic T lymphocyte; and OX39, antiinterleukin-2 receptor. No difference of graft rejection was found between the two treated groups (FK506 1.66 ± 0.49 versus cyclosporine 1.45 ± 0.37), but the FK506 group showed severe graft coronary disease (FK506 2.14 ± 0.82 versus cyclosporine 0.78 ± 0.17; p <0.01) in this model. In flow-cytometric analysis, we found an increased proportion of OX8-positive lymphocytes (FK506 25.7 ± 6.4 versus cyclosporine 4.9 ± 2.4, p <0.01). These results suggest that suppression of cytotoxic T lymphocytes may be involved in graft coronary disease.

UR - http://www.scopus.com/inward/record.url?scp=0026781512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026781512&partnerID=8YFLogxK

M3 - Article

C2 - 1379829

AN - SCOPUS:0026781512

VL - 11

SP - 757

EP - 762

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 4 I

ER -